Pharsight

1. Antara (micronized) patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8026281	LUPIN	Treating metabolic syndrome with fenofibrate	Apr, 2025 (1 year, 6 months from now)
US9314447	LUPIN	Reduced dose pharmaceutical compositions of fenofibrate	May, 2033 (9 years from now)

Drugs and Companies using FENOFIBRATE ingredient

Market Authorisation Date: 30 November, 2004

Treatment: Treating severe hypertriglyceridemia; Treating primary hypercholesterolemia and mixed dyslipidemia

Dosage: CAPSULE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
43 mg and 130 mg	15 Sep, 2008	1	01 Mar, 2012	20 Aug, 2020	Extinguished

Strength	Dosage	Availability
30MG	CAPSULE;ORAL	Prescription
43MG	CAPSULE;ORAL	Prescription
87MG	CAPSULE;ORAL	Discontinued
90MG	CAPSULE;ORAL	Prescription
130MG	CAPSULE;ORAL	Prescription

ANTARA (MICRONIZED) family patents

2. Sesquient patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9750822	LUPIN	Sulfoalkyl ether cyclodextrin compositions	Mar, 2029 (5 years from now)
US7635773	LUPIN	Sulfoalkyl ether cyclodextrin compositions	Mar, 2029 (5 years from now)
US8410077	LUPIN	Sulfoalkyl ether cyclodextrin compositions	Mar, 2029 (5 years from now)
US9200088	LUPIN	Sulfoalkyl ether cyclodextrin compositions	Mar, 2029 (5 years from now)
US9493582	LUPIN	Alkylated cyclodextrin compositions and processes for preparing and using the same	Feb, 2033 (9 years from now)

Drugs and Companies using FOSPHENYTOIN SODIUM ingredient

Market Authorisation Date: 05 November, 2020

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
EQ 100MG PHENYTOIN NA/2ML (EQ 50MG PHENYTOIN NA/ML)	SOLUTION;INTRAVENOUS	Discontinued
EQ 500MG PHENYTOIN NA/10ML (EQ 50MG PHENYTOIN NA/ML)	SOLUTION;INTRAVENOUS	Discontinued

SESQUIENT family patents

3. Solosec patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10857133	LUPIN	Secnidazole for use in the treatment of bacterial vaginosis	Sep, 2035 (11 years from now)
US11324721	LUPIN	Secnidazole for use in the treatment of trichomoniasis	Sep, 2035 (11 years from now)
US11602522	LUPIN	Secnidazole for use in the treatment of sexually transmitted infection	Sep, 2035 (11 years from now)
US10335390	LUPIN	Secnidazole for use in the treatment of bacterial vaginosis	Sep, 2035 (11 years from now)
US11000507	LUPIN	Secnidazole for use in the treatment of bacterial vaginosis	Sep, 2035 (11 years from now)
US11020377	LUPIN	Secnidazole for use in the treatment of bacterial vaginosis	Sep, 2035 (11 years from now)
US11000508	LUPIN	Secnidazole for use in the treatment of trichomoniasis	Sep, 2035 (11 years from now)
US10682338	LUPIN	Secnidazole for use in the treatment of bacterial vaginosis	Sep, 2035 (11 years from now)
US10849884	LUPIN	Secnidazole for use in the treatment of bacterial vaginosis	Sep, 2035 (11 years from now)
US11684607	LUPIN	Secnidazole for use in the treatment of bacterial vaginosis	Sep, 2035 (11 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Sep 15, 2022
New Indication (I)	Jun 30, 2024
New Patient Population (NPP)	Jan 26, 2025
Generating Antibiotic Incentives Now (GAIN)	Sep 15, 2027

Drugs and Companies using SECNIDAZOLE ingredient

NCE-1 date: 2026-09-15

Market Authorisation Date: 15 September, 2017

Treatment: Treatment of bacterial vaginosis in female patients 12 years of age and older; Treatment of bacterial vaginosis in adult women; Treatment of trichomoniasis in adults; Treatment of trichomoniasis in pa...

Dosage: GRANULE;ORAL